Tranexamic acid - An old drug still going strong and making a revival

Thrombosis Research

Volumn 135, Issue 2, 2015, Pages 231-242

  Tengborn, Lilian ^a   Blombäck, Margareta ^b   Berntorp, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antifibrinolytics; Bleeding; Fibrinolysis; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; MOUTHWASH; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTERY THROMBOSIS; ARTHROPLASTY; BIRTH; BLEEDING DISORDER; CARDIOPULMONARY BYPASS; CHILD; DIARRHEA; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EPISTAXIS; FIBRINOLYSIS; GENETIC DISORDER; GYNECOLOGIC SURGERY; HEART SURGERY; HEREDITARY BLEEDING DISORDER; HUMAN; HYSTERECTOMY; JAPAN; LIVER SURGERY; MAJOR SURGERY; MAXIMUM PLASMA CONCENTRATION; MENORRHAGIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE TRAUMA; NAUSEA; OPTIMAL DRUG DOSE; ORAL SURGERY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPINE SURGERY; SUBARACHNOID HEMORRHAGE; SURVIVAL; SWEDEN; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; TONSILLECTOMY; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT SURGERY; VEIN THROMBOSIS; FEMALE; HEMORRHAGE;

ANTIFIBRINOLYTIC AGENTS; FEMALE; HEMORRHAGE; HUMANS; TRANEXAMIC ACID;

EID: 84921451901     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.012     Document Type: Review

References (135)

1. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978;272:549-50.
2. Wiman B, Wallen P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res 1977;10:213-22.
3. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980;65:290-7.
4. Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011;117:6371-4.
5. Bajzar L, Jain N, Wang P, Walker JB. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 2004;32:S320-4.
6. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986;68:275-80.
7. Kluft C, Verheijen JH, Jie AF, Rijken DC, Preston FE, Sue-Ling HM, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fastacting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985;45:605-10.
8. Miles LA, Parmer RJ. Plasminogen receptors: the first quarter century. Semin Thromb Hemost 2013;39:329-37.
9. Okamoto S, Okamoto U. Amino-methyl-cyclohexane-carboxylic acid: AMCHA. A new potent inhibitor of fibrinolysis. Keio J Med 1962;11:105-15.
10. Okamoto S, Sato S, Takada Y, Okamoto U. An Active Stereo-Isomer (Trans-Form) of Amcha and Its Antifibrinolytic (Antiplasminic) Action in Vitro and in Vivo. Keio J Med 1964;13:177-85.
11. Melander B, Gliniecki G, Granstrand B, Hanshoff G. Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copenh) 1965;22:340-52.
12. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.
13. Blomback B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982;25:51-70.
14. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992;267:24259-63.
15. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007;5:2408-14.
16. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002;99:175-9.
17. Andersson L, Nilsson IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N Y Acad Sci 1968;146:642-58.
18. Andersson L, Nilsson IM, Nilehn JE, Hedner U, Granstrand B, Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 1965;2:230-47.
19. Eriksson O, Kjellman H, Schannong M. The biological availability of Cyklokapron tablets compared with Cyklokapron solution administered orally. Stockholm, Sweden: Kabi AB; 1971.
20. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981;20:65-72.
21. Ahlberg A, Eriksson O, Kjellman H. Diffusion of tranexamic acid to the joint. Acta Orthop Scand 1976;47:486-8.
22. Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970;49:241-2.
23. Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14:41-7.
24. Williams-Johnson JA, McDonald AH, Strachan GG, Williams EW. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. West Indian Med J 2010;59:612-24.
25. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011;15:R117.
26. Agency MPA. www.lakemedelsverket.se. [Accessed 9 Dec 2014].
27. European Medicines Agency. Committee for proprietary medicinal products (CPMP) opinion following an article 10 referral: CYKLO-f (tranexamic acid); 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cyklo-f/human-referral-000097.jsp&mid=WC0b01ac0580024e9a#. Accessed October 25, 2014.
28. US Food and Drug Administration. Drugs@FDA: Lysteda (tranexamic acid) label information; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022430s002lbl.pdf. Accessed October 25, 2014.
29. Beno S, Ackery A, Callum J, Rizoli S. Tranexamic acid in pediatric trauma: why not? Crit Care 2014;18:313.
30. Koo JR, Lee YK, Kim YS, Cho WY, Kim HK, Won NH. Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid). Nephrol Dial Transplant 1999;14:750-2.
31. Odabas AR, Cetinkaya R, Selcuk Y, Kaya H, Coskun U. Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A. Nephrol Dial Transplant 2001;16:189-90.
32. Peces R, Aguilar A, Vega C, Cuesta E, Peces C, Selgas R. Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria. Nefrologia 2012;32:160-5.
33. Alameel T, West M. Tranexamic Acid treatment of life-threatening hematuria in polycystic kidney disease. Int J Nephrol 2011;2011:203579.
34. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995;102:401-6.
35. Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A-a two-centre experience. Haemophilia 2012;18:544-9.
36. Vermylen J, Verhaegen-Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh 1968;20:583-7.
37. Nilsson IM. Haemorrhagic and Thrombotic Diseases. London: John Wiley & Sons, Ltd; 1974.
38. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86:714-5.
39. Ross J, Al-Shahi Salman R. The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. Curr Drug Saf 2012;7:44-54.
40. Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg (Br) 2011;93:39-46.
41. Tan J, Chen H, Liu Q, Chen C, Huang W. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res 2013;184:880-7.
42. Forbes CD, Barr RD, Reid G, Thomson C, Prentice CR, McNicol GP, et al. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br Med J 1972;2:311-3.
43. Ramstrom G, Blomback M. Tooth extractions in hemophiliacs. Int J Oral Surg 1975;4:1-17.
44. Vinckier F, Vermylen J. Dental extractions in hemophilia: reflections on 10 years' experience. Oral Surg Oral Med Oral Pathol 1985;59:6-9.
45. Frachon X, Pommereuil M, Berthier AM, Lejeune S, Hourdin-Eude S, Quero J, et al. Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:270-5.
46. Morimoto Y, Yoshioka A, Sugimoto M, Imai Y, Kirita T. Haemostatic management of intraoral bleeding in patients with von Willebrand disease. Oral Dis 2005;11:243-8.
47. Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004;10:218-31.
48. Sindet-Pedersen S, Stenbjerg S. Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg 1986;44:703-7.
49. Ramstrom G, Blomback M, Egberg N, Johnsson H, Ljungberg B, Schulman S. Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). Int J Oral Maxillofac Surg 1989;18:320-2.
50. Waly NG. Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions. Egypt Dent J 1995;41:961-8.
51. Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia 2000;6:533-6.
52. Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 2000;6:71-7.
53. Jimenez-Yuste V, Prim MP, De Diego JI, Villar A, Quintana M, Rabanal I, et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 2002;128:1365-8.
54. Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost 1989;62:767-71.
55. Yilmaz D, Akin M, Ay Y, Balkan C, Celik A, Ergun O, et al. A single centre experience in circumcision of haemophilia patients: Izmir protocol. Haemophilia 2010;16:888-91.
56. Lofqvist T, Sanzen L, Petersson C, Nilsson IM. Total hip replacement in patients with hemophilia. 13 hips in 11 patients followed for 1-16 years. Acta Orthop Scand 1996;67:321-4.
57. Schulman S, Loogna J, Wallensten R. Minimizing factor requirements for surgery without increased risk. Haemophilia 2004;10(Suppl. 4):35-40.
58. Hallberg L, Nilsson L. Determination of Menstrual Blood Loss. Scand J Clin Lab Invest 1964;16:244-8.
59. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-51.
60. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97:734-9.
61. Rybo G. Clinical and experimental studies on menstrual blood loss. Acta Obstet Gynecol Scand 1966;45(Suppl. 7):1-23.
62. Gleeson N, Devitt M, Sheppard BL, Bonnar J. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol 1993;100:768-71.
63. Nilsson L, Rybo G. Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation. Acta Obstet Gynecol Scand 1965;44:467-73.
64. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970;4:214-6.
65. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274-7.
66. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313:579-82.
67. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-83.
68. Leminen H, Hurskainen R. Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. Int J Womens Health 2012;4:413-21.
69. Matteson KA, Rahn DD, Wheeler II TL, Casiano E, Siddiqui NY, Harvie HS, et al. Non-surgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol 2013;121:632-43.
70. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006;26:673-8.
71. Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002;13:225-31.
72. Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212-20.
73. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:865-75.
74. Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol 2011;205(319):e1-7.
75. Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010:CD007872.
76. Roberts I, Ker K. Tranexamic acid for postpartum bleeding. Int J Gynaecol Obstet 2011;115:220-1.
77. Abdel-Aleem H, Alhusaini TK, Abdel-Aleem MA, Menoufy M, Gulmezoglu AM. Effectiveness of tranexamic acid on blood loss in patients undergoing elective cesarean section: randomized clinical trial. J Matern Fetal Neonatal Med 2013;26:1705-9.
78. Shakur H, Elbourne D, Gulmezoglu M, Alfirevic Z, Ronsmans C, Allen E, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010;11:40.
79. Martin-Hirsch PP, Bryant A. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2013;12:CD001421.
80. Caglar GS, Tasci Y, Kayikcioglu F, Haberal A. Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 2008;137:227-31.
81. Bjorlin G, Nilsson IM. Tooth extractions in hemophiliacs after administration of a single dose of factor VIII or factor IX concentrate supplemented with AMCA. Oral Surg Oral Med Oral Pathol 1973;36:482-9.
82. Sindet-Pedersen S. Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J Clin Pharmacol 1987;27:1005-8.
83. Ramstrom G, Sindet-Pedersen S, Hall G, Blomback M, Alander U. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. J Oral Maxillofac Surg 1993;51:1211-6.
84. Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case-control study. Thromb Haemost 2010;104:972-5.
85. Chan CC, Chan YY, Tanweer F. Systematic review and meta-analysis of the use of tranexamic acid in tonsillectomy. Eur Arch Otorhinolaryngol 2013;270:735-48.
86. Brum MR, Miura MS, Castro SF, Machado GM, Lima LH, Lubianca Neto JF. Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. Int J Pediatr Otorhinolaryngol 2012;76:1401-5.
87. Albirmawy OA, Saafan ME, Shehata EM, Basuni AS, Eldaba AA. Topical application of tranexamic acid after adenoidectomy: a double-blind, prospective, randomized, controlled study. Int J Pediatr Otorhinolaryngol 2013;77:1139-42.
88. Petruson B. Epistaxis A clinical study with special reference to fibrinolysis. Acta Otolaryngol Suppl 1974;317:1-73.
89. Gaillard S, Dupuis-Girod S, Boutitie F, Riviere S, Moriniere S, Hatron PY, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 2014;12:1494-502.
90. Cox HT, Poller L, Thomson JM. Evidence for the release of gastric fibrinolytic activity into peripheral blood. Gut 1969;10:404-7.
91. Gluud LL, Klingenberg SL, Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012;1:CD006640.
92. Franchini M, Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014;112:427-31.
93. Benoni G, Björkman S, Fredin H. Application of pharmacokinetic data from healthy volunteers for the prediction of plasma concentration of tranexamic acid in surgical patients. Clin Drug Invest 1995;10:280-7.
94. Zhou XD, Tao LJ, Li J, Wu LD. Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials. Arch Orthop Trauma Surg 2013;133:1017-27.
95. Clave A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients. Orthop Traumatol Surg Res 2012;98:484-90.
96. Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand 2000;71:250-4.
97. Imai N, Dohmae Y, Suda K, Miyasaka D, Ito T, Endo N. Tranexamic acid for reduction of blood loss during total hip arthroplasty. J Arthroplasty 2012;27:1838-43.
98. Li ZJ, Fu X, Xing D, Zhang HF, Zang JC, Ma XL. Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. Eur Spine J and the European Section of the Cervical Spine Research Society 2013;22:1950-7.
99. Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. Knee 2013;20:300-9.
100. Chang CH, Chang Y, Chen DW, Ueng SW, Lee MS. Topical tranexamic Acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty. Clin Orthop Relat Res 2014;472:1552-7.
101. Krohn CD, Sorensen R, Lange JE, Riise R, Bjornsen S, Brosstad F. Tranexamic acid given into the wound reduces postoperative blood loss by half in major orthopaedic surgery. Eur J Surg Suppl 2003;57-61.
102. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995;82:383-92.
103. Fiechtner BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver Jr WC, et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001;92:1131-6.
104. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002;97:390-9.
105. Sharma V, Fan J, Jerath A, Pang KS, Bojko B, Pawliszyn J, et al. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia 2012;67:1242-50.
106. Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011;24:92-7.
107. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010;110:350-3.
108. Schlag MG, Hopf R, Zifko U, Redl H. Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. Acta Neurochir (Wien) 2002;144:63-9.
109. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012;122:4654-66.
110. Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila) 2012;7:229-41.
111. Grassin-Delyle S, Tremey B, Abe E, Fischler M, Alvarez JC, Devillier P, et al. Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2013;111:916-24.
112. Sigaut S, Tremey B, Ouattara A, Couturier R, Taberlet C, Grassin-Delyle S, et al. Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology 2014;120:590-600.
113. Waldow T, Szlapka M, Haferkorn M, Burger L, Plotze K, Matschke K. Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc 2013;55:457-68.
114. Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology 2013;118:853-62.
115. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010;148:507-21.
116. Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012;10:1312-9.
117. Agarwal A, Sharma N, Vij V. Point-of-care coagulation monitoring during liver transplantation. Trends Anaesth Crit Care 2013;3:42-8.
118. Gurusamy KS, Li J, Sharma D, Davidson BR. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev Oct 7 2009;4:CD008085.
119. Rannikko A, Petas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology 2004;64:955-8.
120. Crescenti A, Borghi G, Bignami E, Bertarelli G, Landoni G, Casiraghi GM, et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ 2011;343:d5701.
121. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013;11:307-14.
122. Dirkmann D, Gorlinger K, Gisbertz C, Dusse F, Peters J. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. Anesth Analg 2012;114:1182-8.
123. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013;17:1-79.
124. Gruen RL, Jacobs IG, Reade MC. PATCH-Trauma study. Trauma and tranexamic acid. Med J Aust 2013;199:310-1.
125. Perel P, Al-Shahi Salman R, Kawahara T, Morris Z, Prieto-Merino D, Roberts I, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury-a nested randomised, placebo-controlled trial. Health Technol Assess 2012;16(iii-xii):1-54.
126. Dewan Y, Komolafe EO, Mejia-Mantilla JH, Perel P, Roberts I, Shakur H, et al. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012;13:87.
127. Roos YB, Rinkel GJ, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003:CD001245.
128. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2013;8:CD001245.
129. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002;97:771-8.
130. Germans MR, Post R, Coert BA, Rinkel GJ, Vandertop WP, Verbaan D. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials 2013;14:143.
131. Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg 2003;96:923-8.
132. Weber CF, Gorlinger K, Byhahn C, Moritz A, Hanke AA, Zacharowski K, et al. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol 2011;28:57-62.
133. He S, Johnsson H, Zabczyk M, Hultenby K, Cao H, Blomback M. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor. Br J Haematol 2013;160:806-16.
134. Bringing women to the forefront of science and medicine. Lancet 2012;379:867.
135. Wiman B. Tests used in the clinical evaluation of the fibrinolytic system; 2008. Klinisk Biokemi i Norden [special issue].